PMID: 11335136May 4, 2001Paper

Cytotoxic factor-autoantibodies: possible role in the pathogenesis of dengue haemorrhagic fever

FEMS Immunology and Medical Microbiology
U C ChaturvediA S Mustafa

Abstract

During dengue virus infection a unique cytokine, cytotoxic factor (hCF), is produced that is pathogenesis-related and plays a key role in the development of dengue haemorrhagic fever (DHF). However, what regulates the adverse effects of hCF is not known. We have previously shown that anti-hCF antibodies raised in mice, neutralise the pathogenic effects of hCF. In this study we have investigated the presence and levels of hCF-autoantibodies in sera of patients with various severity of dengue illness (n=136) and normal healthy controls (n=50). The highest levels of hCF-autoantibodies (mean+/-S.D.=36+/-20 U ml(-1)) were seen in patients with mild illness, the dengue fever (DF), and 48 out of 50 (96%) of the sera were positive. On the other hand the hCF-autoantibody levels declined sharply with the development of DHF and the levels were lowest in patients with DHF grade IV (mean+/-S.D.=5+/-2 U ml(-1); P=<0.001 as compared to DF). Only one of the 13 DHF grade IV patients had an antibody level above the 'cut-off' value (mean plus 3 S.D. of the control sera). The analysis of data with respect to different days of illness further showed that the highest levels of hCF-autoantibodies were present in DF patients at >9 days of illness. Mor...Continue Reading

References

Apr 1, 1991·The Journal of General Virology·U C ChaturvediA Mathur
Oct 1, 1994·Immunology Today·R Debets, H F Savelkoul
May 1, 1994·Clinical and Experimental Immunology·U C ChaturvediR Dhawan
Jun 1, 1996·Clinical and Experimental Immunology·A MisraU C Chaturvedi
Jun 5, 1998·Immunology Today·K BendtzenM Svenson
Jun 6, 1998·European Journal of Clinical Investigation·K Bendtzen
Jun 24, 2000·FEMS Immunology and Medical Microbiology·U C ChaturvediA S Mustafa

❮ Previous
Next ❯

Citations

Sep 10, 2003·Vojnosanitetski pregled. Military-medical and pharmaceutical review·Ivanko BojićVesna Begović
Apr 27, 2010·Indian Journal of Dermatology·Padmalal GurugamaSuranjith L Seneviratne
Jun 21, 2002·The American Journal of the Medical Sciences·Michael S BronzeRonald A Greenfield
Sep 19, 2007·Tropical Medicine & International Health : TM & IH·Jose A SuayaMichael B Nathan
Jan 25, 2007·Journal of Medical Virology·Lukkana SuksanpaisanDuncan R Smith
Jun 19, 2007·FEMS Immunology and Medical Microbiology·Umesh C ChaturvediRachna Nagar
Jun 5, 2008·FEMS Immunology and Medical Microbiology·Atanu Basu, Umesh C Chaturvedi
Feb 26, 2009·FEMS Immunology and Medical Microbiology·Umesh C Chaturvedi, Rachna Nagar
Oct 14, 2009·Clinical Microbiology Reviews·Byron E E MartinaAlbert D M E Osterhaus
May 26, 2012·FEMS Immunology and Medical Microbiology·Xin FangXiancai Rao
Feb 12, 2009·Journal of Biosciences·U C Chaturvedi, Rachna Nagar
May 4, 2001·FEMS Immunology and Medical Microbiology·A S MustafaU C Chaturvedi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.